Developer docs
API playgroundTry for free, no card

Search company profiles

Imperative Care

Full company profile

uuid00006ro

Namestring
Imperative Care
Legal namestring
Imperative Care, Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Imperative Care, Inc. is a Campbell, California-based commercial-stage medical technology company founded in 2015 that develops and markets thrombectomy devices for ischemic stroke, pulmonary embolism, venous thromboembolism, and peripheral vascular disease. The company's Stroke Portfolio centers on the Zoom Stroke System, which integrates Zoom Intracranial Access, Zoom Aspiration Catheters, and Continuous Dual Aspiration (CDAT) technology for fast and effective clot removal from access through reperfusion, with multi-center real-world data reporting a median procedure time of 17 minutes using ADAPT 2.0 across 124 patients. The Vascular Portfolio consists of the Symphony Thrombectomy System, which received FDA clearance in August 2025 for treating acute pulmonary embolism and has treated over 500 PE patients commercially, and the Prodigy Thrombectomy System for acute limb ischemia, the latter built on the 2021 acquisition of Truvic Medical. The company is also developing the Telos endovascular robotic platform to bring precision, standardization, and remote access to thrombectomy procedures, though it is not yet approved for sale.

Imperative Care generates revenue through direct hardware sales of FDA-cleared thrombectomy systems to hospitals, stroke centers, interventional neuroradiology suites, pulmonary embolism treatment centers, and vascular surgery departments across the United States, supported by an enterprise field sales motion targeting interventional cardiologists, neuroradiologists, and vascular surgeons. The company invests heavily in clinical evidence generation, including the SYMPHONY-PE trial (109 intermediate-risk PE patients with favorable safety profile and no device-related serious adverse events) and the CLEAR-IT observational study enrolling up to 750 patients across up to 50 U.S. sites, and disseminates findings through peer-reviewed journals such as Circulation: Cardiovascular Interventions and at medical conferences such as the Society of Vascular and Interventional Neurology Annual Meeting.

The company has raised approximately $659 million in total funding across multiple rounds, including a $260 million Series D led by D1 Capital Partners in July 2021, a $150 million Series E led by Ally Bridge Group in July 2024, and an oversubscribed $100 million convertible note financing in March 2026 co-led by Elevage Medical Technologies and Perceptive Advisors with participation from Bain Capital Life Sciences, Catalio Capital Management, Ally Bridge Group, Brown Advisory, and Longaeva Partners. Imperative Care is a privately held company with 251-500 employees, operating through subsidiaries including Truvic Medical, with leadership including Chairman and CEO Farhad Khosravi, CFO Matthew Garrett, CTO Yi Yang, CCO Jay Martin, and founder Nick Hopkins.

Short descriptiontext

Imperative Care is a commercial-stage medical technology company developing FDA-cleared thrombectomy devices (Zoom Stroke System, Symphony, Prodigy) for hospitals and interventional centers treating ischemic stroke, pulmonary embolism, and acute limb ischemia, with a robotic platform (Telos) in development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersCampbell, United States
HQ citystring
Campbell
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
thrombectomy medical devices, neurovascular intervention systems, ischemic stroke treatment, pulmonary embolism devices, endovascular robotic platform
Industry2 codes
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neurovascular and Vascular Thrombectomy Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Imperative Care generates revenue through the sale of its thrombectomy medical devices and systems to hospitals and healthcare providers. The company is a commercial-stage medtech with multiple FDA-cleared products including the Zoom Stroke System, Symphony Thrombectomy System, and Prodigy Thrombectomy System. Revenue is derived from direct hospital procurement and clinical adoption of its stroke and vascular thrombectomy portfolios.

vcnewsdaily.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Zoom Stroke System
Description

Complete system for fast and effective clot removal in ischemic stroke patients - from access through reperfusion.

imperativecare.com
+3 more records
Core offering1 text field

Imperative Care develops and commercializes FDA-cleared thrombectomy medical devices for ischemic stroke, venous thromboembolism/pulmonary embolism, and acute limb ischemia. Its commercial portfolio includes the Zoom Stroke System (Zoom Aspiration Catheters, Zoom Intracranial Access, and CDAT technology), the Symphony Thrombectomy System (FDA-cleared August 2025), and the Prodigy Thrombectomy System, with the Telos endovascular robotic platform under development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Early mechanical thrombectomy within 12 hours of diagnosis for intermediate-risk PE patients showed mean pulmonary artery pressure reduction of 8.6 vs 5.8 for late treatment group (p=0.006)
+4 more records
Product overview1 text field

Imperative Care is a medical technology company with a dual-portfolio approach: a Stroke Portfolio centered on the Zoom Stroke System (including Zoom Intracranial Access, Zoom Aspiration Catheters, and CDAT technology) for ischemic stroke treatment, and a Vascular Portfolio featuring the Symphony Thrombectomy System for venous thromboembolism/pulmonary embolism and the Prodigy Thrombectomy System for acute limb ischemia. The company is also developing the Telos robotic platform for endovascular procedures. In 2021, Imperative Care acquired Truvic Medical to enhance its peripheral vascular disease treatment capabilities.

Product and service3 records
1Zoom Stroke System
CategoryNeurovascular Thrombectomy System
Description

A complete stroke treatment system from access through reperfusion for fast and effective clot removal in a wide range of vessels for patients with ischemic stroke, intended for hospitals, stroke centers, and interventional neuroradiology suites.

2Symphony Thrombectomy System
CategoryVascular Thrombectomy System
Description

Aspiration-based thrombectomy system for the treatment of venous thromboembolism including pulmonary embolism in intermediate-risk PE patients, intended for cardiovascular and pulmonary care centers.

3Prodigy Thrombectomy System
CategoryPeripheral Vascular Thrombectomy System
Description

Thrombectomy system for treatment of acute limb ischemia and peripheral arterial thromboembolism, intended for vascular surgery and interventional radiology departments.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Truvic Medical
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-01
Description

Truvic Medical, a peripheral thrombectomy innovator, was acquired by Imperative Care in July 2021 to form a strategic network of subsidiaries focused on vascular interventions. Truvic operates as a subsidiary of Imperative Care advancing vascular intervention products including the Prodigy Thrombectomy System.

finsmes.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Penumbra is the closest direct competitor, with the Penumbra System aspiration catheters and JET family of aspiration thrombectomy devices targeting ischemic stroke, and the Indigo System for peripheral and pulmonary embolism thrombectomy — directly overlapping with both the Zoom and Symphony/Prodigy franchises.

TypeDirect peer
Description

Stryker's Neurovascular division (acquired via Concentric Medical) markets the Trevo retriever and other stroke intervention devices; combined with its acquisition of Inari Medical, Stryker competes directly with Imperative Care across stroke and venous thromboembolism thrombectomy.

TypeBroad incumbent
Description

Medtronic's Neurovascular portfolio (Solitaire, React, Riptide aspiration) competes in ischemic stroke thrombectomy, while its broader cardiovascular franchise overlaps with vascular indications served by Symphony and Prodigy.

4Johnson & Johnson (Cerenovus)
TypeDirect peer
Description

Cerenovus (J&J's neurovascular business) markets the EmboTrap and CERENOVUS stroke thrombectomy solutions, directly competing with the Zoom Stroke System in the same hospital accounts.

TypeDirect peer
Description

AngioDynamics markets the AlphaVac mechanical thrombectomy system for pulmonary embolism and venous thromboembolism, directly competing with Symphony in the same PE indication.

TypeDirect peer
Description

Inari Medical (acquired by Stryker) developed the FlowTriever system for pulmonary embolism and the ClotTriever for peripheral venous thromboembolism — direct competitors to Symphony and Prodigy in the venous and PE thrombectomy space.

TypeBroad incumbent
Description

Boston Scientific's peripheral intervention portfolio (AngioJet, thrombectomy catheters) overlaps with Prodigy in peripheral arterial/venous thrombectomy, and its broader interventional franchise competes for hospital budgets in the same procedure suites.

TypeDirect peer
Description

Teleflex (via its Vascular Solutions / Arrow portfolio) markets the Mermaid and other peripheral thrombectomy tools, partially overlapping with Prodigy in peripheral arterial disease treatment.

TypeBroad incumbent
Description

Edwards is a major cardiovascular medical device incumbent with growing presence in structural heart and critical care; its scale and hospital relationships create competitive pressure across the vascular thrombectomy purchasing environment.

TypeRegional player
Description

Terumo markets interventional and vascular access products (including aspiration and thrombectomy tools) primarily in Japan and Asia-Pacific, with overlapping technology that may compete with Imperative Care in international expansion scenarios.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Imperative Care

Neurovascular and Vascular Thrombectomy Medical Devicesimperativecare.com

Imperative Care is a commercial-stage medical technology company developing FDA-cleared thrombectomy devices (Zoom Stroke System, Symphony, Prodigy) for hospitals and interventional centers treating ischemic stroke, pulmonary embolism, and acute limb ischemia, with a robotic platform (Telos) in development.

What Imperative Care does

Imperative Care, Inc. is a Campbell, California-based commercial-stage medical technology company founded in 2015 that develops and markets thrombectomy devices for ischemic stroke, pulmonary embolism, venous thromboembolism, and peripheral vascular disease. The company's Stroke Portfolio centers on the Zoom Stroke System, which integrates Zoom Intracranial Access, Zoom Aspiration Catheters, and Continuous Dual Aspiration (CDAT) technology for fast and effective clot removal from access through reperfusion, with multi-center real-world data reporting a median procedure time of 17 minutes using ADAPT 2.0 across 124 patients. The Vascular Portfolio consists of the Symphony Thrombectomy System, which received FDA clearance in August 2025 for treating acute pulmonary embolism and has treated over 500 PE patients commercially, and the Prodigy Thrombectomy System for acute limb ischemia, the latter built on the 2021 acquisition of Truvic Medical. The company is also developing the Telos endovascular robotic platform to bring precision, standardization, and remote access to thrombectomy procedures, though it is not yet approved for sale.

Imperative Care generates revenue through direct hardware sales of FDA-cleared thrombectomy systems to hospitals, stroke centers, interventional neuroradiology suites, pulmonary embolism treatment centers, and vascular surgery departments across the United States, supported by an enterprise field sales motion targeting interventional cardiologists, neuroradiologists, and vascular surgeons. The company invests heavily in clinical evidence generation, including the SYMPHONY-PE trial (109 intermediate-risk PE patients with favorable safety profile and no device-related serious adverse events) and the CLEAR-IT observational study enrolling up to 750 patients across up to 50 U.S. sites, and disseminates findings through peer-reviewed journals such as Circulation: Cardiovascular Interventions and at medical conferences such as the Society of Vascular and Interventional Neurology Annual Meeting.

The company has raised approximately $659 million in total funding across multiple rounds, including a $260 million Series D led by D1 Capital Partners in July 2021, a $150 million Series E led by Ally Bridge Group in July 2024, and an oversubscribed $100 million convertible note financing in March 2026 co-led by Elevage Medical Technologies and Perceptive Advisors with participation from Bain Capital Life Sciences, Catalio Capital Management, Ally Bridge Group, Brown Advisory, and Longaeva Partners. Imperative Care is a privately held company with 251-500 employees, operating through subsidiaries including Truvic Medical, with leadership including Chairman and CEO Farhad Khosravi, CFO Matthew Garrett, CTO Yi Yang, CCO Jay Martin, and founder Nick Hopkins.

Imperative Care firmographics

Firmographics
Name
Imperative Care
Legal name
Imperative Care, Inc.
Website
https://imperativecare.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
251–500 employees
Short description
Imperative Care is a commercial-stage medical technology company developing FDA-cleared thrombectomy devices (Zoom Stroke System, Symphony, Prodigy) for hospitals and interventional centers treating ischemic stroke, pulmonary embolism, and acute limb ischemia, with a robotic platform (Telos) in development.
Ownership category
akta.pro rank

Imperative Care industry classification

Industry
Product category
Neurovascular and Vascular Thrombectomy Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Thrombectomy medical devices
  • Neurovascular intervention systems
  • Ischemic stroke treatment
  • Pulmonary embolism devices
  • Endovascular robotic platform

Where Imperative Care is headquartered

Location

Headquarters

HQ city
Campbell
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Imperative Care business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Others

Revenue model

  1. Medical Device Sales: Imperative Care generates revenue through the sale of its thrombectomy medical devices and systems to hospitals and healthcare providers. The company is a commercial-stage medtech with multiple FDA-cleared products including the Zoom Stroke System, Symphony Thrombectomy System, and Prodigy Thrombectomy System. Revenue is derived from direct hospital procurement and clinical adoption of its stroke and vascular thrombectomy portfolios.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Imperative Care product offering

Product offering

Core offering

Imperative Care develops and commercializes FDA-cleared thrombectomy medical devices for ischemic stroke, venous thromboembolism/pulmonary embolism, and acute limb ischemia. Its commercial portfolio includes the Zoom Stroke System (Zoom Aspiration Catheters, Zoom Intracranial Access, and CDAT technology), the Symphony Thrombectomy System (FDA-cleared August 2025), and the Prodigy Thrombectomy System, with the Telos endovascular robotic platform under development.

Product overview

Imperative Care is a medical technology company with a dual-portfolio approach: a Stroke Portfolio centered on the Zoom Stroke System (including Zoom Intracranial Access, Zoom Aspiration Catheters, and CDAT technology) for ischemic stroke treatment, and a Vascular Portfolio featuring the Symphony Thrombectomy System for venous thromboembolism/pulmonary embolism and the Prodigy Thrombectomy System for acute limb ischemia. The company is also developing the Telos robotic platform for endovascular procedures. In 2021, Imperative Care acquired Truvic Medical to enhance its peripheral vascular disease treatment capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • Zoom Stroke System: Complete system for fast and effective clot removal in ischemic stroke patients - from access through reperfusion.
  • Symphony Thrombectomy System
  • Prodigy Thrombectomy System
  • Telos Robotic Platform

Products and services

  • Zoom Stroke System A complete stroke treatment system from access through reperfusion for fast and effective clot removal in a wide range of vessels for patients with ischemic stroke, intended for hospitals, stroke centers, and interventional neuroradiology suites.
  • Symphony Thrombectomy System Aspiration-based thrombectomy system for the treatment of venous thromboembolism including pulmonary embolism in intermediate-risk PE patients, intended for cardiovascular and pulmonary care centers.
  • Prodigy Thrombectomy System Thrombectomy system for treatment of acute limb ischemia and peripheral arterial thromboembolism, intended for vascular surgery and interventional radiology departments.

Quantifiable outcome

  • Early mechanical thrombectomy within 12 hours of diagnosis for intermediate-risk PE patients showed mean pulmonary artery pressure reduction of 8.6 vs 5.8 for late treatment group (p=0.006)
  • +4 more outcomes

Companies that use Imperative Care

Customer profile

Segments3 records

Ideal customer profiles3 records

Imperative Care technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Imperative Care partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Truvic MedicalcoreStrategic or Co-development Partner · 1 July 2021Truvic Medical, a peripheral thrombectomy innovator, was acquired by Imperative Care in July 2021 to form a strategic network of subsidiaries focused on vascular interventions. Truvic operates as a subsidiary of Imperative Care advancing vascular intervention products including the Prodigy Thrombectomy System.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Imperative Care competitors and assessment

Company assessment

Direct peers

  • Penumbra: Penumbra is the closest direct competitor, with the Penumbra System aspiration catheters and JET family of aspiration thrombectomy devices targeting ischemic stroke, and the Indigo System for peripheral and pulmonary embolism thrombectomy — directly overlapping with both the Zoom and Symphony/Prodigy franchises.
  • Stryker (Neurovascular): Stryker's Neurovascular division (acquired via Concentric Medical) markets the Trevo retriever and other stroke intervention devices; combined with its acquisition of Inari Medical, Stryker competes directly with Imperative Care across stroke and venous thromboembolism thrombectomy.
  • Johnson & Johnson (Cerenovus): Cerenovus (J&J's neurovascular business) markets the EmboTrap and CERENOVUS stroke thrombectomy solutions, directly competing with the Zoom Stroke System in the same hospital accounts.
  • AngioDynamics: AngioDynamics markets the AlphaVac mechanical thrombectomy system for pulmonary embolism and venous thromboembolism, directly competing with Symphony in the same PE indication.
  • Inari Medical: Inari Medical (acquired by Stryker) developed the FlowTriever system for pulmonary embolism and the ClotTriever for peripheral venous thromboembolism — direct competitors to Symphony and Prodigy in the venous and PE thrombectomy space.
  • Teleflex: Teleflex (via its Vascular Solutions / Arrow portfolio) markets the Mermaid and other peripheral thrombectomy tools, partially overlapping with Prodigy in peripheral arterial disease treatment.

Broad incumbents

  • Medtronic: Medtronic's Neurovascular portfolio (Solitaire, React, Riptide aspiration) competes in ischemic stroke thrombectomy, while its broader cardiovascular franchise overlaps with vascular indications served by Symphony and Prodigy.
  • Boston Scientific: Boston Scientific's peripheral intervention portfolio (AngioJet, thrombectomy catheters) overlaps with Prodigy in peripheral arterial/venous thrombectomy, and its broader interventional franchise competes for hospital budgets in the same procedure suites.
  • Edwards Lifesciences: Edwards is a major cardiovascular medical device incumbent with growing presence in structural heart and critical care; its scale and hospital relationships create competitive pressure across the vascular thrombectomy purchasing environment.

Regional players

  • Terumo: Terumo markets interventional and vascular access products (including aspiration and thrombectomy tools) primarily in Japan and Asia-Pacific, with overlapping technology that may compete with Imperative Care in international expansion scenarios.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Imperative Care social profiles

Digital presence

Imperative Care financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Imperative Care leadership team

Management profile

Number of profiles

Profiles11 records

Imperative Care subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Imperative Care funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Imperative Care M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imperative Care

What does Imperative Care do?

Imperative Care develops and commercializes FDA-cleared thrombectomy medical devices for ischemic stroke, venous thromboembolism/pulmonary embolism, and acute limb ischemia. Its commercial portfolio includes the Zoom Stroke System (Zoom Aspiration Catheters, Zoom Intracranial Access, and CDAT technology), the Symphony Thrombectomy System (FDA-cleared August 2025), and the Prodigy Thrombectomy System, with the Telos endovascular robotic platform under development.

Is Imperative Care a public or private company?

Imperative Care is a private company. It is classified as venture growth investor backed and is currently operating.

When was Imperative Care founded?

Imperative Care was founded in 2015. It employs 251 to 500 people.

Where is Imperative Care based?

Imperative Care is headquartered in Campbell, United States, in the North America region.

How does Imperative Care make money?

One revenue line is on record: medical Device Sales.

Who are Imperative Care's main competitors?

Direct peers on record are Penumbra, Stryker (Neurovascular), Johnson & Johnson (Cerenovus), AngioDynamics, Inari Medical and Teleflex. Broad incumbents are Medtronic, Boston Scientific and Edwards Lifesciences. Terumo is listed as a regional player.

Does Imperative Care have an API?

No public API is recorded for Imperative Care.

What industry is Imperative Care in?

Imperative Care's product category is Neurovascular and Vascular Thrombectomy Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanImperative Care Adds Two Directors to Its BoardImperative Care appointed Brett Wall and Dr. Josh Makower to its board of directors. Wall brings over two decades of experience in neurovascular and neuroscience businesses, while Makower represents Elevage Medical Technologies. Holly Sheffield stepped down from the board after five years of service.Business Wire BlogImperative Care’s First-in-Field Analysis Provides Encouraging Safety Findings for Women with Pulmonary EmbolismA sex-specific analysis of the SYMPHONY-PE IDE trial found women and men with intermediate-risk pulmonary embolism experienced comparable clot burden reduction and safety outcomes after aspiration thrombectomy with the Symphony system. Women showed greater baseline cardiac stress but similar short-term results, with no deaths or device-related serious adverse events through 30 days.FinancialContent Business PageImperative Care’s First-in-Field Analysis Provides Encouraging Safety Findings for Women with Pulmonary EmbolismImperative Care presented findings from a sex-specific analysis of the SYMPHONY-PE IDE trial at TCT 2026, showing women and men with intermediate-risk pulmonary embolism experienced substantial clot burden reduction and improved right-heart function. No deaths or device-related serious adverse events occurred in either group through 30 days, and women had lower RV/LV ratios at 48 hours.Law360Imperative Gets PTAB To Trim Inari Medical Device ClaimsThe Patent Trial and Appeal Board invalidated claims in an Inari Medical patent on surgical valves, handing a win to challenger Imperative Care in its California infringement lawsuit. The decision furthered Imperative's defense against the device maker.MedicalEconomicsImperative Care launches new dual aspiration technology for stroke treatmentImperative Care Inc. has launched Zoom DuoPort, a new technology enabling physicians to perform stroke thrombectomy using its Continuous Dual Aspiration Technique (CDAT). The company cited data from the Imperative Trial showing that this dual aspiration method achieved a 19-minute median time to reperfusion, reported as the fastest in major prospective trials. This launch represents an enhancement to the FDA-cleared Zoom Stroke System, aiming to streamline acute ischemic stroke treatment procedures.MedicalEconomicsImperative Care wins FDA Clearance for device to treat pulmonary embolismImperative Care Inc. has received FDA clearance to market its Symphony Thrombectomy System for the treatment of pulmonary embolism, expanding the device's approved use beyond venous thrombosis. The decision follows positive results from the SYMPHONY-PE Study, which demonstrated the system's safety and effectiveness in reducing clot burden while allowing physicians greater procedural control. This regulatory milestone introduces a new frontline interventional option for a condition affecting approximately 900,000 people annually in the United States.MassDeviceImperative Care launches new guidewire purpose-built for strokeImperative Care launched the Ikon 24 Pro guidewire, a next-generation neurovascular device purpose-built for treating stroke. The device features a uniform 0.024-inch diameter wire throughout its length, a progressive support profile matched to the company's Zoom catheters, and enhanced tactile feedback for improved vascular access during stroke procedures. The launch follows Imperative Care's $100 million fundraising earlier this year and reflects the company's commitment to innovating stroke treatment through its stroke portfolio.Mpo-magImperative Care Releases Ikon 24 Pro Neurovascular GuidewireImperative Care launched Ikon 24 Pro, a neurovascular guidewire for aspiration thrombectomy, featuring a uniform 0.024" length and transitional shaft matching its Zoom catheters. The design aims to enhance procedural speed and efficiency, with early adopter Kunal Vakharia citing consistent navigability and control.YahooImperative Care reports SYMPHONY-PE trial data for pulmonary embolismImperative Care reported post-hoc analysis results from the SYMPHONY-PE trial showing that early mechanical thrombectomy within 12 hours of diagnosis for intermediate-risk pulmonary embolism patients led to greater short-term improvements in right ventricular function and pulmonary artery pressure compared to later treatment. Out of 109 trial participants, 44% received early treatment, with the early group showing an average pulmonary artery pressure reduction of 8.6 versus 5.8 for the late group, and an RV/LV ratio reduction of 0.52 versus 0.37. The analysis found no significant difference in major adverse events between groups and no device-related serious adverse events or deaths, suggesting a favorable safety profile for the Symphony thrombectomy system.